Clinical data I. Clinical experience with tenofovir in combination with nonnucleoside analogue transcriptase inhibitors;Datos clínicos I. Experiencia clínica de tenofovir en combinaciones con inhibidores no análogos de la transcriptasa inversa

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 26, Issue SUPPL. 8, 2008, Pages 7-12

  de la Serna, José Ignacio Bernardino ^a   Rillo, Marta Mora ^a   López, José Ramón Arribas ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Adverse effects; Efficacy; Nonnucleoside analogue transcriptase inhibitors; Resistance; Tenofovir DF

Indexed keywords

ATAZANAVIR; CHOLESTEROL; CREATININE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; TRIACYLGLYCEROL; ZIDOVUDINE;

ADVERSE OUTCOME; ANEMIA; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; ASTHENIA; BONE DENSITY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME INHIBITION; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; LIVER TOXICITY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PRACTICE GUIDELINE; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; VERTEBRA DISLOCATION; VIRUS LOAD;

EID: 74549202287     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1157/13126266     Document Type: Article

References (23)

1. European Medicines Agency. Comité de medicamentos de uso humano (CHMP). Informe Europeo público de autorización (EPAR) (accedido, 4 Mar 2008). Disponible en: http://www.emea.europa.eu/humandocs/PDFs /EPAR/viread/351001en6.pdf
2. Recomendaciones de GESIDA/Plan Nacional sobre el SIDA respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana. Actualización enero 2008 (accedido, 7 Mar 2008). Disponible en: http://www.gesida.seimc.org/index.asp
3. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 29, 2008;1-128 (accedido 7 Mar 2008). Disponible en: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
4. European AIDS Clinical Society (EACS). Guidelines for the clinical management and treatment on HIV infected adults in Europe. Versión 2. Diciembre 2007 (accedido 7 Mar 2008). Disponible en: http://www.eacs.eu/guide/index. htm
5. Podzamczer D., Ferrer E., Gatell J.M., Niubo J., Dalmau D., León A., et al. Early virological failure with a combination of tenofovir, didanosine and efavirenz. Antiviral Therapy 10 (2005) 171-177
6. Maitland D., Moyle G., Hand J., Mandalia S., Boffito M., Nelson M., et al. Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12 week results from a randomized trial. AIDS 19 (2005) 1183-1188
7. Torti C., Quiros-Roldon E., Regazzi M., Antinoni A., Patroni A., Villani P., et al., Collaboration Group of the MASTER Cohort. Early virological failure alter tenofovir + didanosine + efafirenz combination in HIV-positive patients upon starting antirretroviral therapy. Antiviral Therapy 10 (2005) 505-513
8. Barlett J.A., Chen S.S., and Quinn J.B. Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview. HIV Clin Trials 8 (2007) 221-226
9. Gallant J.E., Staszewski S., Pozniak A.L., DeJesús E., Suleiman J.M.A.H., Miller M.D., et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral naive patients: a 3-year randomized trial. JAMA 292 (2004) 191-201
10. Pozniak A.L., Gallant J.E., Staszewski S., Suleiman J.M., DeJesús E., Lu B., et al. Similar 96-week efficacy profile regardless of baseline characteristic variable for tenofovir disoproxil fumarate (tdf) versus stavudine (d4t) when used in combination with lamivudine and efavirenz in antiretroviral naive patients. Antivir Ther 8 Suppl 1 (2003) abstract on. 559
11. Moreno S., Domingo P., Palacios R., Santos J., Falcó V., Murillas J., et al., Recover Study Group. Renal safety of tenofovir disoproxil fumarate in HIV-1 treatment-experienced patients with adverse events related to prior NRTI use: data from a prospective, observational, multicenter study. J Acquir Immune Defic Syndr 42 (2006) 385-387
12. Gallant J.E., Parish M.A., Keruly J.C., and Moore R.D. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 40 (2005) 1194-1198
13. Izzedine H., Hulot J.S., Vittecoq D., Gallant J.E., Staszewski S., Launay-Vacher V., et al. Team Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naïve HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant 20 (2005) 743-746
14. Margot N.A., Lu B., Cheng A., and Millar M.D. Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoroxil fumarate or stavudine with lamivudine and efavirenz in study 903. HIV Medicine 7 (2006) 442-450
15. Valdez J.R., Cassetti I., Suleiman J.M., Etzel A., Zhong L., Holmes C.B., et al. The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in HIV-1-infected patients: three-year follow-up after switching therapy. HIV Clin Trials 8 (2007) 381-390
16. Gallant J.E., DeJesús E., Arribas J.R., Pozniak A.L., Gazzard B., Campo R.E., et al. Tenofovir DF, emtricitabine and efavirenz vs. zidovudine, lamivudine and efavirenz for VIH. N Engl J Med 354 (2006) 251-260
17. Pozniak A.L., Gallant J.E., DeJesús E., Arribas J.R., Gazzard B., Campo R.E., et al. Tenofocir disoproxil fumarate, emtricitabine, and efavirenz versus fixed dose zidovudine/lamivudine and efavirenz in antirretroviral-naive patients. Virologic, immunologic, and morphologic changes: a 96-week analysis. J Acquir Immune Defic Syndr 43 (2006) 535-540
18. Arribas J.R., Pozniak A.L., Gallant J.E., DeJesús E., Gazzard B., Campo R.E., et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr 47 (2008) 74-78
19. European Medicines Agency. Comité de medicamentos de uso humano (CHMP). Informe Europeo público de autorización (EPAR) (accedido 4 Mar 2008). Disponible en: http://www.emea.europa.eu/humandocs/Humans/EPAR/atripla/atripla.htm
20. Mc Coll D.J., Margot N., Chuang S.M., Chen S.S., Cheng A.K., and Miler M.D. Final week 144 resistance analysis of study 934: no K65R detected and lower frequency of M184V on tenofovir DF + emtricitabine + efavirenz compared to combivir + efavirenz. 11th European AIDS Conference. Madrid. October 24-27 (2007) P3.1/08
21. Rey D., Schmitt M.P., Hoizey G., Meyer P., Chavanet P., Allavena C., et al. Early virologic non-response to once daily combination of lamivudine, tenofovir and nevirapine in ART-naïve HIV-infected patients: preliminary results of the DAUFIN study. 14th Conference on retroviruses and opportunistic infections. Los Angeles. February 25-28 (2007) 503
22. Lapadula G., Torti C., Quirós-Roldán E., Costarelli S., Tirelli V., and Carosi G. Risk of early virological failure to tenofovir/emtricitabine once daily plus nevirapine twice daily in HIV-infected patients naïve to antiretroviral therapy. 11th European AIDS Conference. Madrid. October 24-27 (2007) P7.3/10
23. DeJesús E., Young B., Fisher A., Ebrahimi R., Maa J.-F., Seekins D., et al. Virologic supresión is mantained alter change to efavirenz/emtricitabine/tenofovir disoproxil fumarate single tablet regimen (EFV/FTC/EFV) vs continuation of current antirretroviral therapy: Study AI266073 results of 24 week interim analyses. 11th European AIDS Conference. Madrid. October 24-27 (2007) PS.7/6